Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for KB803 (Ophthalmic B-VEC) in Dystrophic epidermolysis bullosa. The expected timing is based on the latest available company guidance and may change.
IOLITE study. 5/6/24- Aligned w/ FDA. 6/24/25- First patient dosed. 11/03/25:- IOLITE Phase 3 enrollment ongoing; complete enrollment before YE 2025. 02/17/26:- IOLITE dosing regimen simplified; enrollment ongoing; expect enrollment completion in H1 2026 and topline Phase 3 data in 2026. 05/04/26:- IOLITE fully enrolled (16 patients); expect Phase 3 IOLITE topline data in Q4 2026. 08/03/26:- IOLITE topline Phase 3 data remains on track for Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.